Roundview Capital LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 2.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,599 shares of the conglomerate’s stock after buying an additional 685 shares during the period. Roundview Capital LLC’s holdings in Danaher were worth $2,469,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after buying an additional 520,776 shares during the period. BlackRock Inc. boosted its position in Danaher by 3.2% during the 2nd quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after buying an additional 1,233,876 shares during the period. FMR LLC boosted its position in Danaher by 0.9% during the 2nd quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after buying an additional 183,183 shares during the period. Parnassus Investments CA boosted its position in Danaher by 0.3% during the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after buying an additional 29,381 shares during the period. Finally, Flossbach Von Storch AG boosted its position in Danaher by 17.2% during the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after buying an additional 994,902 shares during the period. 75.88% of the stock is owned by institutional investors and hedge funds.

Danaher Co. (NYSE DHR) opened at $95.41 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $104.82. The company has a market cap of $66,370.00, a price-to-earnings ratio of 27.26, a price-to-earnings-growth ratio of 1.99 and a beta of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.03. The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. Danaher’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the business earned $1.05 EPS. sell-side analysts predict that Danaher Co. will post 4.37 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, January 26th. Investors of record on Friday, December 29th were paid a $0.14 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. Danaher’s payout ratio is 16.00%.

Several brokerages have weighed in on DHR. Royal Bank of Canada reissued a “hold” rating and set a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Credit Suisse Group increased their price target on shares of Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Stifel Nicolaus upped their price objective on shares of Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Morgan Stanley upped their price objective on shares of Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Finally, Argus upped their price objective on shares of Danaher from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Danaher has a consensus rating of “Buy” and a consensus price target of $100.13.

In related news, SVP Angela S. Lalor sold 42,988 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the completion of the transaction, the senior vice president now directly owns 82,008 shares in the company, valued at approximately $8,388,598.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 274,913 shares of company stock valued at $27,729,293. 12.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/13/roundview-capital-llc-has-2-47-million-holdings-in-danaher-co-dhr.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.